Coronary Artery Disease (CAD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Coronary Artery Disease (CAD) Market Outlook

Thelansis’s “Coronary Artery Disease (CAD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Coronary Artery Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Coronary Artery Disease (CAD) Overview

Coronary artery disease (CAD) encompasses a range of clinical conditions resulting from inadequate blood flow to the heart muscle, primarily caused by the deposition of atheroma in the artery walls, leading to narrowing or blockage of the arteries. When the heart doesn't receive enough oxygen-rich blood, symptoms may manifest:

1. Insufficient blood flow can result in chest pain or discomfort, known as angina, accompanied by shortness of breath. These symptoms may exacerbate the progression of plaque buildup, further constricting the coronary arteries.
2. Complete blockage of blood flow can precipitate a heart attack, characterized by symptoms such as angina, weakness, lightheadedness, nausea, cold sweats, pain or discomfort in the arms or shoulder, and shortness of breath.

In terms of gender, mortality rates are higher among women compared to men, often due to atypical anginal symptoms and diagnostic challenges. Non-invasive diagnostic testing for CAD is less sensitive in women, leading to lower rates of coronary angiography and revascularization—however, women undergoing angiography exhibit lower rates of obstructive CAD. The delayed onset of obstructive CAD in women, typically 7-10 years later than in men, contributes to a worse prognosis, especially among older women with comorbidities. Diagnostic measures commonly include Electrocardiogram (ECG or EKG), Echocardiography (echo or cardiac ultrasound), and Cardiac calcium scoring. The burden of CAD is significant, with more than four out of five cardiovascular disease (CVD) deaths attributed to heart attacks and strokes, a third of which occur prematurely in individuals under 70 years of age. Treatment options for CAD encompass lifestyle modifications, medications, medical interventions, and cardiac rehabilitation. Additionally, CAD can lead to complications such as arrhythmias, heart failure, and mortality. An estimated 15.5 million Americans aged 20 and above are affected by CAD. Glanzmann Thrombasthenia is a genetic bleeding disorder caused by mutations in the ITGA2B or ITGB3 gene. The disorder results in quantitative and qualitative abnormalities of the integrin alphaIIb/beta3 (αIIbβ3) receptor protein necessary for platelet aggregation and clot formation. The deficiency or dysfunction of αIIbβ3 leads to the inability of platelets to bind together and form clots, causing moderate to severe bleeding. The disorder has been classified into three types based on the availability of αIIbβ3. Type I is the most common, with less than 5% of normal αIIbβ3 levels. Type II has 5-20% of normal levels, and the variant type has adequate levels but only nonfunctional αIIbβ3. In some cases, the cause of the disorder is unknown. The diagnostic features of Glanzmann Thrombasthenia include the absence of platelet aggregation and recurring episodes of mucocutaneous and spontaneous bleeding. Purpura, epistaxis, and gingival bleeding are common manifestations, and RBC transfusion may be required in severe cases. The risk of severe bleeding decreases with age, but fatal bleeding episodes can occur at any point in the lifespan of a patient with Glanzmann Thrombasthenia.

• In general population prevalence of Glanzmann thrombasthenia is estimated to be 1 per 1,000.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: